Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors
PHASE2CompletedINTERVENTIONAL
Enrollment
16
Participants
Timeline
Start Date
December 3, 2014
Primary Completion Date
June 30, 2020
Study Completion Date
December 1, 2020
Conditions
Solid Tumor
Interventions
DRUG
Gefitinib
Gefitinib 250mg will be administered orally daily
Trial Locations (1)
Unknown
Samsung Medical Center, Seoul
All Listed Sponsors
lead
Samsung Medical Center
OTHER
NCT02447419 - Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors | Biotech Hunter | Biotech Hunter